The use of Esketamine in CT-guided percutaneous liver tumor ablation reduces the consumption of remifentanil: a randomized, controlled, double-blind trial.

导出 LinkOut

翻译打印收藏纠错

作者： Yanbing,Su ^[1] ; Jianxing,Zhang ^[1] ; Huanwei,Wang ^[1] ; Yangkui,Gu ^[1] ; Handong,Ouyang ^[1] ; Wan,Huang ^[1]

作者单位： Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. ^[1]

关键词 Esketamine ablation analgesia liver tumor sedation

DOI 10.21037/atm-22-2756

PMID 35845514

发布时间 2022-07-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Annals of translational medicine

2022年10卷12期

704页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

The use of Esketamine in CT-guided percutaneous liver tumor ablation reduces the consumption of remifentanil: a randomized, controlled, double-blind trial.

Annals of translational medicine

相似文献

Annals of translational medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The use of Esketamine in CT-guided percutaneous liver tumor ablation reduces the consumption of remifentanil: a randomized, controlled, double-blind trial.

Annals of translational medicine

相似文献

Annals of translational medicine

相关期刊

检索历史清除